| Literature DB >> 25834987 |
Jan Glaser1, Martina Schultheis2, Heidrun Moll3, Banasri Hazra4, Ulrike Holzgrabe5.
Abstract
The chloroform extract of Valeriana wallichii (V. wallichii) rhizomes was investigated to elucidate the structures responsible for reported antileishmanial activity. Besides bornyl caffeate (1, already been reported by us previously), bioassay-guided fractionation resulted in two additional cinnamic acid derivatives 2-3 with moderate leishmanicidal activity. The structure of a novel nepetolactone derivative 4 having a cinnamic acid moiety was elucidated by means of spectral analysis. To the best of our knowledge villoside aglycone (5) was isolated from this plant for the first time. The bioassay-guided fractionation yielded two new (compounds 6-7) and two known valtrates (compounds 8-9) with leishmanicidal potential against Leishmania major (L. major) promastigotes. In addition, β-bisabolol (10), α-kessyl alcohol (11), valeranone (12), bornyl isovalerate (13) and linarin-2-O-methylbutyrate (14) were identified. This is the first report on the isolation of 4'-demethylpodophyllotoxin (15), podophyllotoxin (16) and pinoresinol (17) in V. wallichii. In total thirteen known and four new compounds were identified from the extract and their cytotoxic and antileishmanial properties were evaluated.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25834987 PMCID: PMC6272176 DOI: 10.3390/molecules20045740
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Isolated and identified compounds from V. wallichii extract. Abbr.: Iv = isovaleryl; Miv = β-methylisovaleryl; IvaIva = α-isovaleroyloxyisovaleryl; Ac = acetyl.
Figure 2Overview of the bioassay-guided fractionation of V. wallichii extract. Method A: preparative HPLC (250 mm × 10 mm, 5 µm, Nucleosil 100-5); H2O (a): MeOH (b), gradient: 70% b (0 min), 75% b (7 min), 100% b (25 min), 70% b (30 min); flow rate: 3.3 mL/min. Method B: preparative HPLC (125 mm × 10 mm, 5 µm, Nucleodur Sphinx RP); H2O (a): CH3CN (b), gradient: 10% b (0–2 min), 30% b (2–15 min), 65% b (15–22 min), 10% b (22–24 min); flow rate: 4.4 mL/min. Method C: flash chromatography (silica gel; MeOH/CHCl3, 4.8:0.2, v/v). Method D: column chromatography (silica gel; MeOH/CHCl3, 4.8:02, v/v).
Figure 3Key 1H-1H-COSY, HMBC and NOESY correlations of 4.
Figure 4Key 1H-1H-COSY, HMBC and NOESY correlations of villoside aglycone 5.
1H- and 13C-NMR data of new and known valtrates 6–9 in CDCl3.
| Position | 13C of 6 | 1H of 6 | 13C of 7 | 1H of 7 | 13C of 8 [ | 1H of 8 | 13C of 9 [ | 1H of 9 [ | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 89.2 | 6.22 (d; 4.7; 1H) | 89.2 | 6.27 (d; 4.2; 1H) | 92.5 | 6.25 (d; 10.0; 1H) | 89.4 | 6.19 (d; 5.1; 1H) | |
| 3 | 141.0 | 6.44 (br s; 1H) | 140.9 | 6.44 (br s; 1H) | 148.0 | 6.68 (br s; 1H) | 141.0 | 6.45 (br s; 1H) | |
| 4 | 112.8 | 112.9 | 108.7 | 113.0 | |||||
| 5 | 31.8 | 2.90 (dd; 9.2; 11.0; 1H) | 31.4 | 2.90 (dd; 7.8; 8.0; 1H) | 139.1 | 32.6 | 2.91 (m; 1H) | ||
| 6 | 34.9 | 2.1 (m; 2H) | 34.7 | 2.12 (m; 2H) | 117.6 | 5.77 (t; 2.8; 1H) | 35.0 | 2.04–2.13 (m; 2H) | |
| 7 | 80.1 | 4.99 (t; 4.5; 1H) | 80.4 | 5.03 (t; 4.7; 1H) | 83.1 | 5.47 (d; 2.8; 1H) | 80.0 | 5.01 (t; 3.9; 1H) | |
| 8 | 80.9 | 80.9 | 80.2 | 81.8 | |||||
| 9 | 44.5 | 2.42 (dd; 6.1; 15.0; 1H) | 44.7 | 2.44 (dd; 4.1; 9.6; 1H) | 48.4 | 2.94 (dd; 2.5; 10.0; 1H) | 45.4 | 2.45 (dd; 5.9; 8.1; 1H) | |
| 10 | 66.8 | 4.29 (d; 11.5; 1H) | 66.6 | 4.22 (s; 2H) | 65.5 | 4.32 (d; 11.6; 1H) | 49.1 | 3.71 (d; 11.4; 1H) | |
| 11 | 63.4 | 4.42 (d; 12.3; 1H) | 63.3 | 4.42 (d; 12.3; 1H) | 60.9 | 4.64 (d; 12.5; 1H) | 63.3 | 4.42 (d; 12.3; 1H) | |
| R1 | 1 | 171.3 | 171.1 | 170.8 d | 171.1 | ||||
| 2 | 41.3 | 2.40 (m; 2H) | 43.3 b | 2.23 (m; 4H) | 43.2 | 2.32 (d; 7.0; 2H) | 43.4 g | 2.09–2.13 (m; 4H) | |
| 3 | 31.8 | 1.90 (m; 1H) | 25.6 c | 2.07–2.15 (m; 3H) | 25.7 | 2.05–2.09 (m; 2H) | 25.7 h | 2.00–2.06 (m; 2H) | |
| 4 | 19.5 | 0.97 (m; 3H) | 22.3 a | 0.96 (m; 18H) | 22.3 f | 0.93 (d; 6.6; 6H) g | 22.4 i | 0.97 (d; 6.7; 6H) g | |
| 5 | 29.3 | 1.40 (m; 2H) | 22.3 a | 0.96 (m; 18H) | 22.3 f | 0.93 (d; 6.6; 6H) g | 22.4 i | 0.97 (d; 6.7; 6H) g | |
| 6 | 11.2 | 0.90 (m; 3H) | |||||||
| R2 | 1 | 169.7 | 173.0 | 170.8 d | 172.9 | ||||
| 2 | 43.0 | 2.30–2.35 (m; 4H) | 43.5 | 2.19 (m; 2H) | 20.9 | 2.04 (s; 3H) | 43.3 g | 2.09–2.13 (m; 4H) | |
| 3 | 25.7 | 2.11 (m; 2H) | 25.7 c | 2.07–2.15 (m; 3H) | 25.6 h | 2.00–2.06 (m; 2H) | |||
| 4 and 5 | 22.4 | 0.98 (d; 6.9; 12H) | 22.4 a | 0.96 (m; 18H) | 22.4 i | 0.95 (d; 6.6; 6H) g | |||
| R3 | 1 | 170.2 | 170.3 | 171.8 | 169.8 | ||||
| 2 | 21.0 | 2.07 (s; 3H) | 21.0 | 2.05 (s; 3H) | 43.4 | 2.14 (m; 2H) | 21.0 | 2.08 (s; 3H) | |
| 3 | 25.6 e | 2.05–2.09 (m; 2H) | |||||||
| 4 and 5 | 22.3 f | 0.95 (d; 6.6; 6H) g | |||||||
| R4 | 1 | 173.2 | 172.9 | 173.8 | |||||
| 2 | 76.9 | 4.74 (d; 4.8; 1H) | 43.1 b | 2.23 (m; 4H) | 43.0 | 2.20 (m; 2H) | |||
| 3 | 30.0 | 2.23 (m; 1H) | 25.7 c | 2.07–2.15 (m; 3H) | 25.6 e | 2.17–2.25 (m; 1H) | |||
| 4 | 18.8 | 1.02 (m; 3H) | 22.3 a | 0.96 (m; 18H) | 22.3 f | 0.99 (d; 6.6; 6H) g | |||
| 5 | 17.3 | 1.00 (m; 3H) | 22.3 a | 0.96 (m; 18H) | 22.3 f | 0.99 (d; 6.6; 6H) g | |||
| 6 | 172.9 | ||||||||
| 7 | 43.0 | 2.30–2.35 (m; 4H) | |||||||
| 8 | 25.7 | 2.11 (m; 2H) | |||||||
| 9 and 10 | 22.4 | 0.98 (d; 6.9; 12H) |
a–i Assignments may be interchanged.
Figure 5Key HMBC correlations of valtrates 6 and 7.
Antileishmanial activity and cytotoxicity of fractions containing isolated compounds.
| Compound | IC50 ( | IC50 (J774.1) [µg/mL] |
|---|---|---|
| 48.8 * | 8.3 * | |
| 16.7 | 34.7 | |
| 12.2 | 8.6 | |
| >100 | >100 | |
| >100 | 17.5 | |
| 52.2 | 37.1 | |
| 60.8 | 42.6 | |
| >100 * | >100 * | |
| >100 | 10.8 | |
| >100 | < | |
| >100 | ||
| >100 | < | |
| 36.2 * | 56.5 * |
* These data were gained from pure or synthesized compounds and are therefore given in µM. a There was a small amount of another valtrate present. b The fraction of kessyl alcohol was contaminated with an non-identified valtrate (~10% by NMR integration).